| # |
Company Name
|
Industry Name
|
Latest Price (Rs.)
|
Price Change
Rs (%) |
Market Cap
|
Net Sales
(Rs. Cr.) |
Latest EPS
(Rs.) |
Net Profit
Margin % |
Latest
P/E |
Latest
P/BV |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Reddys Labs. | Pharmaceuticals& Drugs | 1,186.4 |
-4.6 (-0.39%) |
Mid Cap | 33,700 | 38.6 | 11.44 | 30.9 | 2.6 | |
| Cipla | Pharmaceuticals& Drugs | 1,408.4 |
-11.6 (-0.82%) |
Mid Cap | 28,163 | 41.7 | 13.45 | 34 | 3.3 | |
| Lupin | Pharmaceuticals& Drugs | 2,191.2 |
16.2 (0.74%) |
Mid Cap | 27,958 | 120.9 | 18.82 | 18 | 4.2 | |
| Zydus Lifesciences | Pharmaceuticals& Drugs | 1,148 |
17.95 (1.59%) |
Mid Cap | 27,148 | 45.2 | 16.54 | 25 | 4.2 | |
| Glenmark Pharma. | Pharmaceuticals& Drugs | 2,440 |
45 (1.88%) |
Mid Cap | 16,983 | 63.7 | 15.9 | 37.6 | 6.2 | |
| Aurobindo Pharma | Pharmaceuticals& Drugs | 1,622 |
18.75 (1.17%) |
Mid Cap | 11,172 | 45.1 | 20.59 | 35.6 | 3.9 | |
| Mankind Pharma | Pharmaceuticals& Drugs | 2,393 |
26 (1.1%) |
Mid Cap | 10,421 | 52.8 | 19.97 | 44.8 | 5.8 | |
| Alkem Laboratories | Pharmaceuticals& Drugs | 5,340.2 |
-6.8 (-0.13%) |
Mid Cap | 9,664 | 178.4 | 22.7 | 30 | 4.4 | |
| Ipca Laboratories | Pharmaceuticals& Drugs | 1,951.9 |
21.7 (1.12%) |
Mid Cap | 7,289 | 49 | 16.38 | 39.4 | 5.9 | |
| Abbott India | Pharmaceuticals& Drugs | 26,501.2 |
65.9 (0.25%) |
Mid Cap | 6,929 | 759.9 | 22.25 | 34.8 | 10.9 | |
| Laurus Labs | Pharmaceuticals& Drugs | 1,888 |
23 (1.23%) |
Mid Cap | 6,813 | 20.2 | 12.82 | 92.2 | 17.9 | |
| Ajanta Pharma | Pharmaceuticals& Drugs | 3,545.2 |
-12 (-0.34%) |
Mid Cap | 5,453 | 90.8 | 19.33 | 39.2 | 9.2 | |
| Glaxosmithkline Phar | Pharmaceuticals& Drugs | 3,027.5 |
47.45 (1.59%) |
Mid Cap | 3,822 | 63.1 | 25.36 | 47.3 | 20 | |
| Biocon | Pharmaceuticals& Drugs | 417.4 |
2.8 (0.68%) |
Mid Cap | 2,346 | 0.6 | 5.85 | 691.6 | 2.5 | |
| Anthem Biosciences | Pharmaceuticals& Drugs | 923.5 |
48.55 (5.55%) |
Mid Cap | 2,089 | 11.1 | 30.95 | 79 | 15.2 |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: